NASDAQ:HSGX Histogenics (HSGX) Stock Price, News & Analysis → Will this $2 AI stock double overnight? (From Behind the Markets) (Ad) Free HSGX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.15▼$1.2950-Day Range$0.16▼$3.0752-Week Range$0.08▼$1.43Volume7.25 million shsAverage Volume9.06 million shsMarket Capitalization$111.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Histogenics alerts: Email Address Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> About Histogenics Stock (NASDAQ:HSGX)Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.Read More Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> HSGX Stock News HeadlinesApril 8, 2023 | thetimes.co.ukFeargal Sharkey: Desperate revival of failed policies doesn’t add upSeptember 21, 2022 | streetinsider.comAspect Biosystems Appoints Three New Board Members - StreetInsider.comApril 25, 2024 | Behind the Markets (Ad)Will this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!September 21, 2022 | businesswire.comAspect Biosystems Appoints Three New Board Members - Business WireAugust 24, 2022 | investing.comAre Ocugen Or Amarin Good Stocks To Buy? - Investing.comAugust 5, 2022 | stockhouse.com2022-08-05 | NDAQ:OCGN | Press Release | Ocugen, Inc. - StockhouseJune 23, 2022 | gurufocus.comOcugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition - GuruFocus.comMay 25, 2022 | uk.investing.comOcugen Diversifies Its Pipeline With New Cell Therapy Platform By Benzinga - Investing.com UKApril 25, 2024 | Behind the Markets (Ad)Will this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!May 25, 2022 | globenewswire.comOcugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition - GlobeNewswireMay 24, 2022 | streetinsider.comOcugen (OCGN) Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition - StreetInsider.comApril 18, 2022 | streetinsider.comForm DEF 14A Aurinia Pharmaceuticals For: Apr 18 - StreetInsider.comMarch 8, 2022 | investorplace.comOcugen Is Two Strikes in With a Third in the Books - InvestorPlaceOctober 26, 2021 | news.yahoo.comCN.ORTH: New Blood on The Board - Yahoo FinanceSeptember 21, 2021 | prnewswire.comGlobal Cell Therapy Market Outlook, Patent & Clinical Trials Report 2021-2028: Clinical & Commercial Insight On 32 Cell Therapies Available & Insight on 1600+ Cell Therapies in Clinical Trials - PRNewswireSeptember 8, 2021 | streetinsider.comForm 8-K APPLIED GENETIC TECHNOLO For: Sep 08 - StreetInsider.comSee More Headlines Receive HSGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Histogenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2018Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical Appliances & Supplies Sub-IndustryN/A Current SymbolNASDAQ:HSGX CUSIPN/A CIK1372299 Webwww.histogenics.com Phone781-547-7900FaxN/AEmployees49Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.96% Return on Assets18.40% Debt Debt-to-Equity RatioN/A Current Ratio4.05 Quick Ratio4.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-118.00Miscellaneous Outstanding Shares94,599,000Free FloatN/AMarket Cap$111.63 million OptionableNot Optionable Beta3.10 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Adam D. Gridley (Age 47)Interim Pres, CEO Treasurer, Sec., Consultant & Director Mr. Jonathan I. Lieber (Age 49)Interim Chief Financial Officer Mr. Stephen R. Kennedy (Age 62)Consultant Key CompetitorsEnvoy MedicalNASDAQ:COCHInogenNASDAQ:INGNCollPlant BiotechnologiesNASDAQ:CLGNVicarious SurgicalNYSE:RBOTMilestone ScientificNYSE:MLSSView All Competitors HSGX Stock Analysis - Frequently Asked Questions How were Histogenics' earnings last quarter? Histogenics Corp (NASDAQ:HSGX) announced its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.10. What other stocks do shareholders of Histogenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Histogenics investors own include Interpace Biosciences (IDXG), Novavax (NVAX), Verastem (VSTM), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Magnegas Applied Tchnlgy Sltns (MNGA), Ocular Therapeutix (OCUL), Trevena (TRVN), OPKO Health (OPK) and Synergy Pharmaceuticals (SGYP). When did Histogenics IPO? Histogenics (HSGX) raised $60 million in an IPO on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager. This page (NASDAQ:HSGX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport SocietyMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Histogenics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
